Attached files

file filename
EX-99.2 - TRANSCRIPT - RadNet, Inc.radnet_8k-ex9902.htm
8-K - FORM 8-K - RadNet, Inc.radnet_8k-080916.htm

Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE

 

RadNet Reports Second Quarter Financial Results and Reaffirms Previously Announced 2016 Guidance Levels

 

·Total Net Revenue, modified for working capital adjustments related to New York acquisitions, (“Adjusted Revenue”), increased 10.0% to $224.6 million in the second quarter of 2016 from $204.3 million in the second quarter of 2015
·Adjusted EBITDA(1) increased 4.7% to $35.1 million in the second quarter of 2016 from $33.5 million in the second quarter of 2015
·Sequentially, as compared to the first quarter of 2016, Adjusted Revenue increased 3.8%, and Adjusted EBITDA(1) increased 29.6%
·Earnings Per Share was $0.09 per share, also modified for New York acquisition-related tax-effective adjustments (“Adjusted Earnings Per Share”), in the second quarter of 2016, an increase from $0.08 from the second quarter of 2015
·Aggregate procedural volumes increased 9.6% and same center volumes increased 0.4% as compared with the second quarter of 2015
·Completed successful refinancing of the majority of our debt facilities on July 1st, effectively extending maturities and providing additional operating flexibility
·Commenced operations of our first health system joint venture in California with Dignity Health

 

 

LOS ANGELES, California, August 9, 2016 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 310 owned and/or operated outpatient imaging centers, today reported financial results for its second quarter of 2016.

 

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “I am very pleased with our operational results this quarter and the improvements we are making to our business. Normalizing our results for the one-time non-cash gains and losses in the quarter related to our New York acquisitions, our business produced double digit revenue growth, positive same store procedural growth for the ninth quarter in a row and higher EBITDA and Earnings as compared with last year’s second quarter. Additionally, sequentially from our first quarter of this year, our EBITDA increased almost 30%, raising EBITDA margins from 12.5% in the first quarter to 15.6% in the second quarter of 2016.”

 

Dr. Berger continued, “I’m excited about the opportunities we have in front of us to continue to expand and improve our business organically, particularly our ability to leverage best practices of the most successful aspects of our business on the east and west coasts. For example, we are pursuing several new health system partnerships on the west coast, a business model that has traditionally been a strength of our east coast operations, and we are looking to expand existing joint ventures on the east coast. During the quarter, we announced and commenced operations with our first California health system partnership with Dignity Health in the city of Glendale. This announcement and other initiatives we are working on in California with our Breastlink and oncology capabilities have created keen interest from other prominent health systems. We are more encouraged than ever that the joint venture partnership model that we’ve successfully demonstrated in the mid-Atlantic and New Jersey marketplaces will become more prominent for our west coast operations in the coming quarters.”

 

 

 

 

 1 

 

 

Dr. Berger added, “Another example of the sharing of best practices between our east and west coast operations is the opportunity to bring capitation and risk-based contracting outside of our California marketplace, where it has been such an integral aspect of how we’ve successfully grown our business. Diagnostic Imaging Group, which we acquired last year, had a small risk-based component of its business. With the combination of DIG’s assets with our other significant New York metropolitan operations which include Lenox Hill Radiology, New York Radiology Partners and our Mid-Rockland Imaging centers, we have begun to initiate meaningful conversations with medical groups on the east coast interested in our risk-based exclusive network contracting capabilities. I’m more confident than ever that this will be the successful model of the post-Affordable Care Act era, and that RadNet will be the first imaging center company to meaningfully align with major capitated medical groups, health systems and Accountable Care Organizations across all of our target markets. We expect to be in a position to discuss these opportunities more meaningfully before year end.”

 

“From a financial perspective, we’ve never been in a stronger position to grow our business. We completed the refinancing of our senior debt facilities on July 1st, where we lengthened the maturities on our debt to 2023 (in the case of our first lien term loan) and 2021 in the case of our senior revolving credit facility. At the same time, we availed ourselves of additional operating flexibility to continue to grow our business and pursue the types of opportunities for expansion that we envision will be available to us over the next several years. We believe that securing our capital structure in a low interest rate environment was prudent and allows us to focus on operations without having concern about risks associated with the capital markets in years to come,” finished Dr. Berger.

 

Second Quarter Financial Results

 

For the second quarter of 2016, RadNet reported Adjusted Revenue of $224.6 million, after adding back $6.1 million of one-time non-cash working capital adjustments related to New York acquisitions which served to lower GAAP Revenue by such an amount during the quarter. Adjusted EBITDA(1) for the second quarter was $35.1 million. Adjusted Revenue increased $20.3 million (or 10.0%) and Adjusted EBITDA(1) increased $1.6 million (or 4.7%) from the second quarter of last year.

 

For the second quarter, RadNet reported Adjusted Net Income of $4.4 million, which is modified by removing certain tax effected non-cash items including (i) the $6.1 million of working capital adjustments mentioned above; (ii) a $5.0 million settlement gain on the return of common stock relating to the acquisition of Diagnostic Imaging Group; and (iii) a $221,000 one-time adjustment to depreciation in conjunction with the finalization of the purchase price allocation related to the Diagnostic Imaging Group acquisition. Adjusted Net Income increased $987,000 over the second quarter of 2015.

 

Per share Adjusted Net Income for the second quarter was $0.09, compared to per share Adjusted Net Income in the second quarter of 2015 of $0.08 (based upon a weighted average number of diluted shares outstanding of 46.9 million and 44.7 million for these periods in 2016 and 2015, respectively).

 

Affecting Net Income in the second quarter of 2016 were certain non-cash expenses and non-recurring items including: $5.0 million settlement gain related to the return of common stock in connection with our acquisition of Diagnostic Imaging Group; $6.1 million charge to Revenue related to working capital adjustments also pertaining to acquisitions we completed in New York; $221,000 of one-time depreciation expense related to the finalization of the purchase price allocation related to the Diagnostic Imaging Group acquisition; $1.0 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $173,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $441,000 loss on the sale of certain capital equipment; and $1.4 million of non-cash amortization of deferred financing costs and discount on debt issuances.

 

For the second quarter of 2016, as compared with the prior year’s second quarter, MRI volume increased 7.5%, CT volume increased 8.9% and PET/CT volume increased 4.8%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 9.6% over the prior year’s second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2016 and 2015, MRI volume increased 3.0%, CT volume increased 4.4% and PET/CT volume increased 1.3%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 0.4% over the prior year’s same quarter.

 

 

 

 2 

 

 

Six Month Financial Results

 

For the six months ended June 30, 2016, RadNet reported Adjusted Revenue of $441.0 million, after adding back $6.1 million of one-time non-cash working capital adjustments related to NY acquisitions which served to lower GAAP Revenue by such an amount during the six month period. Adjusted EBITDA(1) for the six month period in 2016 was $62.2 million. Adjusted Revenue increased $55.4 million (or 14.4%) and Adjusted EBITDA(1) increased $8.5 million (or 15.8%) from the same six month period last year.

 

For the six month period in 2016, RadNet reported Adjusted Net Income of $2.6 million, which is modified by removing certain tax effected non-cash items including (i) the $6.1 million of working capital adjustments mentioned above; (ii) a $5.0 million settlement gain on the return of common stock relating to the acquisition of Diagnostic Imaging Group; and (iii) a $110,000 one-time adjustment to depreciation in conjunction with the finalization of the purchase price allocation related to the Diagnostic Imaging Group acquisition.

 

Adjusted Net Income increased $3.8 million over the six month period of 2015. Per share Adjusted Net Income for the six month period in 2016 was $0.06, compared to per share Adjusted Net Loss in the prior year’s same period of $(0.03) (based upon a weighted average number of diluted shares outstanding of 47.0 million and 43.1 million for these periods in 2016 and 2015, respectively).

 

Affecting operating results in the six months ended June 30, 2016 were certain non-cash expenses and non-recurring items including: $5.0 million settlement gain related to the return of common stock in connection with the acquisition of Diagnostic Imaging Group; $6.1 million charge to Revenue related to a working capital adjustment also pertaining to acquisitions we completed in New York; $110,000 of one-time depreciation expense related to the finalization of the purchase price allocation related to the Diagnostic Imaging Group acquisition; $3.8 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $340,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $441,000 loss on the sale of certain capital equipment; and $2.7 million of non-cash amortization of deferred financing costs and discount on debt issuances.

 

2016 Guidance Update

 

RadNet reaffirms its previously announced 2016 guidance ranges as follows:

 

Total Net Revenue (a) $870 million - $910 million
Adjusted EBITDA(1) $130 million - $140 million
Capital Expenditures (b) $50 million - $55 million
Cash Interest Expense $37 million - $40 million
Free Cash Flow Generation (c)

$40 million - $50 million

     

 

(a)Note the change from prior years. This metric is now presented after the subtraction of bad debt.
(b)Net of proceeds from the sale of equipment, imaging centers and joint venture interests. Represents an increase of $5 million from originally announced guidance range.
(c)Defined by the Company as Adjusted EBITDA(1) less total capital expenditures and cash paid for interest.

 

Dr. Berger added, “We are on track to meet our guidance ranges for the year. All ranges remain unchanged from what we announced earlier in the year with the exception of increasing our targeted capital expenditure range by $5 million. This increase is to fund a replacement program of our computed radiography (CR x-ray) scanners to provide them with digital wireless transmitting capabilities. This will improve quality, lower labor costs and comply with a new CMS ruling which would otherwise lower our x-ray reimbursement from traditional CR systems beginning in 2018.”

 

 

 

 3 

 

 

Conference Call for Today

 

Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter 2016 results on Tuesday, August 9th, 2016 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

 

Conference Call Details:

 

Date: Tuesday, August 9, 2016

Time: 10:30 a.m. Eastern Time

Dial In-Number: 888-471-3820

International Dial-In Number: 719-325-2388

 

It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=120693 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 877-870-5176 from the U.S., or 858-384-5517 for international callers, and using the passcode 3424412.

 

Regulation G: GAAP and Non-GAAP Financial Information

 

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

 

About RadNet, Inc.

 

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 310 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Rhode Island. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,300 employees. For more information, visit http://www.radnet.com.

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning successfully integrating acquired operations, successfully achieving 2015 financial guidance, achieving cost savings, successfully developing and integrating new lines of business, continuing to grow its business by generating patient referrals and contracts with radiology practices, and receiving third-party reimbursement for diagnostic imaging services, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

 

 

 

 4 

 

 

CONTACTS:

 

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial Officer

 

 

 

 

 

 

 

 

 

 5 

 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

 

   June 30,   December 31, 
   2016   2015 
   (unaudited)     
ASSETS
CURRENT ASSETS          
Cash and cash equivalents  $433   $446 
Accounts receivable, net   165,086    162,843 
Current portion of deferred tax assets   22,278    22,279 
Due from affiliates   4,273    4,815 
Prepaid expenses and other current assets   30,511    38,986 
Total current assets   222,581    229,369 
PROPERTY AND EQUIPMENT, NET   250,426    256,722 
OTHER ASSETS          
Goodwill   240,520    239,408 
Other intangible assets   44,032    45,253 
Deferred financing costs   2,012    2,841 
Investment in joint ventures   39,483    33,584 
Deferred tax assets, net of current portion   24,352    24,685 
Deposits and other   4,935    4,565 
Total assets  $828,341   $836,427 
LIABILITIES AND EQUITY          
CURRENT LIABILITIES          
Accounts payable, accrued expenses and other  $108,075   $113,813 
Due to affiliates   8,545    6,564 
Deferred revenue   1,599    1,598 
Current portion of notes payable   21,609    22,383 
Current portion of deferred rent   2,551    2,563 
Current portion of obligations under capital leases   7,713    10,038 
Total current liabilities   150,092    156,959 
LONG-TERM LIABILITIES          
Deferred rent, net of current portion   27,929    26,865 
Line of credit   13,800     
Notes payable, net of current portion   589,177    599,914 
Obligations under capital lease, net of current portion   4,710    6,385 
Other non-current liabilities   5,667    9,843 
Total liabilities   791,375    799,966 
EQUITY          
RadNet, Inc. stockholders' equity:          
Common stock - $.0001 par value, 200,000,000 shares authorized; 46,432,404 and 46,281,189 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively   4    4 
Additional paid-in-capital   196,026    197,297 
Accumulated other comprehensive loss   (169)   (153)
Accumulated deficit   (162,669)   (164,571)
Total RadNet, Inc.'s stockholders' equity   33,192    32,577 
Noncontrolling interests   3,774    3,884 
Total equity   36,966    36,461 
Total liabilities and equity  $828,341   $836,427 

 

 

 

 

 6 

 

 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS EXCEPT SHARE DATA)

(unaudited)

 

   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2016   2015   2016   2015 
NET REVENUE                    
Service fee revenue, net of contractual allowances and discounts  $203,759   $188,403   $404,601   $353,433 
Provision for bad debts   (12,326)   (8,387)   (22,630)   (15,862)
Net service fee revenue   191,433    180,016    381,971    337,571 
Revenue under capitation arrangements   27,132    24,273    52,982    47,985 
Total net revenue   218,565    204,289    434,953    385,556 
OPERATING EXPENSES                    
Cost of operations, excluding depreciation and amortization   194,062    175,796    390,888    344,717 
Depreciation and amortization   15,811    14,941    32,223    29,235 
Loss on sale and disposal of equipment   441    74    441    36 
Severance costs   173    94    340    130 
Total operating expenses   210,487    190,905    423,892    374,118 
INCOME FROM OPERATIONS   8,078    13,384    11,061    11,438 
                     
OTHER INCOME AND EXPENSES                    
Interest expense   10,745    10,423    21,426    20,419 
Meaningful use incentive           (2,808)   (3,270)
Equity in earnings of joint ventures   (3,274)   (3,207)   (5,553)   (4,309)
Gain from return of common stock   (5,032)       (5,032)    
Other expenses   4    413    6    410 
Total other expenses   2,443    7,629    8,039    13,250 
INCOME (LOSS) BEFORE INCOME TAXES   5,635    5,755    3,022    (1,812)
(Provision for) benefit from income taxes   (2,253)   (2,192)   (1,073)   899 
NET INCOME (LOSS)   3,382    3,563    1,949    (913)
Net (loss) income attributable to noncontrolling interests   (243)   168    47    246 
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.                    
COMMON STOCKHOLDERS  $3,625   $3,395   $1,902   $(1,159)
                     
BASIC NET INCOME (LOSS) PER SHARE                    
ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $0.08   $0.08   $0.04   $(0.03)
DILUTED NET INCOME (LOSS) PER SHARE                    
ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS  $0.08   $0.08   $0.04   $(0.03)
WEIGHTED AVERAGE SHARES OUTSTANDING                    
Basic   46,558,944    43,370,024    46,576,631    43,059,686 
Diluted   46,882,383    44,685,599    46,960,226    43,059,686 

 

 

 

 

 7 

 

 

RADNET, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(unaudited)

 

   Six Months Ended June 30,  
   2016   2015 
 CASH FLOWS FROM OPERATING ACTIVITIES          
           
 Net income (loss)  $1,949   $(913)
 Adjustments to reconcile net income (loss)          
 to net cash provided by operating activities:          
 Depreciation and amortization   32,223    29,235 
 Provision for bad debts   22,630    15,862 
 Gain from return of common stock   (5,032)    
 Equity in earnings of joint ventures   (5,553)   (4,309)
 Distributions from joint ventures   2,098    6,195 
 Amortization and write off of deferred financing costs and loan discount   2,738    2,631 
 Loss on sale and disposal of equipment   441#   36 
 Stock-based compensation   3,761    5,571 
 Changes in operating assets and liabilities, net of assets          
 acquired and liabilities assumed in purchase transactions:          
 Accounts receivable   (24,873)   (19,368)
 Other current assets   8,454    (3,058)
 Other assets   220    (3,687)
 Deferred taxes   333    (1,854)
 Deferred rent   1,052    4,602 
 Deferred revenue       (564)
 Accounts payable, accrued expenses and other   10,983    (2,423)
 Net cash provided by operating activities   51,424    27,956 
 CASH FLOWS FROM INVESTING ACTIVITIES          
 Purchase of imaging facilities   (6,603)   (34,407)
 Purchase of property and equipment   (40,267)   (31,649)
 Proceeds from sale of equipment   63    205 
 Cash distribution from existing JV partner   994     
 Equity contributions in existing and purchase of interest in joint ventures   (734)   (265)
 Net cash used in investing activities   (46,547)   (66,116)
 CASH FLOWS FROM FINANCING ACTIVITIES          
 Principal payments on notes and leases payable   (6,310)   (3,969)
 Proceeds from borrowings       74,401 
 Payments on Term Loan Debt   (12,357)   (11,369)
 Deferred financing costs       (531)
 Net proceeds on revolving credit facility   13,800    (15,300)
 Distributions paid to noncontrolling interests   (157)   (613)
 Proceeds from issuance of common stock upon exercise of options/warrants   150    594 
 Net cash (used in) provided by financing activities   (4,874)   43,213 
 EFFECT OF EXCHANGE RATE CHANGES ON CASH   (16)   (41)
 NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (13)   5,012 
 CASH AND CASH EQUIVALENTS, beginning of period   446    307 
 CASH AND CASH EQUIVALENTS, end of period  $433   $5,319 
           
 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
 Cash paid during the period for interest  $18,545   $18,283 

 

 

 8 

 

 

RADNET, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.

COMMON SHAREHOLDERS TO ADJUSTED EBITDA(1)

(IN THOUSANDS)

 

   Three Months Ended
   June 30,
   2016   2015
Net Income Attributable to RadNet, Inc. Common Shareholders  $3,625 $ 3,395
Plus Provision for Income Taxes   2,253   2,192
Plus Other Expenses (Income)   4   413
Less Gain on Acquisition-Related Return of Common Stock   (5,032) 
Plus Acquisition-Related Working Capital Adjustment   6,072  
Plus Interest Expense   10,745   10,423
Plus Severance Costs   173   94
Plus Loss on Sale of Equipment   441   74
Plus Depreciation and Amortization   15,811   14,941
Plus Non Cash Employee Stock Compensation   1,028   2,017
Adjusted EBITDA(1)  $35,120 $ 33,549

 

   Six Months Ended  
   June 30,  
   2016   2015  
Net Loss Attributable to RadNet, Inc. Common Shareholders  $1,902 $ (1,159 )
Plus Provision for (Benefit From) Income Taxes   1,073   (899 )
Plus Other Expenses (Income)   6   410  
Less Gain on Acquisition-Related Return of Common Stock   (5,032)  -  
Plus Acquisition-Related Working Capital Adjustment   6,072   -  
Plus Interest Expense   21,426   20,419  
Plus Severance Costs   340   130  
Plus Loss on Sale of Equipment   441   36  
Plus Depreciation and Amortization   32,223   29,235  
Plus Non Cash Employee Stock Compensation   3,761   5,571  
Adjusted EBITDA(1)  $62,212 $ 53,743  

 

 

 

 

 9 

 

 

PAYOR CLASS BREAKDOWN**

 

  Second Quarter
  2016
Commercial Insurance 56.3%
Medicare 19.7%
Capitation 11.8%
Workers Compensation/Personal Injury 3.9%
Medicaid 3.0%
Other 5.4%
Total 100.0%

 

**Capitation percentage has been calculated based upon its proportion of Revenue Under Capitation Arrangements in the period  to

Service Fee Revenue, Net of Contractual Allowances and Discounts plus Revenue Under Capitation Arrangements. After deducting the capitation percentage from 100%, all other payor class percentages are based upon a proportion to global payments received from consolidated imaging centers from that periods dates of services and excludes payments from hospital contracts, Breastlink, imaging center management fees, eRAD, Imaging on Call and other miscellaneous revenue.


 

RADNET PAYMENTS BY MODALITY *

 

    Second Quarter   Full Year   Full Year   Full Year  
    2016   2015   2014   2013  
                   
MRI   34.7%   35.3%   36.1%   36.3%  
CT   16.0%   15.7%   15.3%   15.5%  
PET/CT   4.9%   5.1%   5.7%   5.6%  
X-ray   9.5%   9.6%   10.2%   10.5%  
Ultrasound   12.5%   11.5%   11.1%   11.0%  
Mammography   16.1%   16.4%   16.5%   15.7%  
Nuclear Medicine   1.2%   1.3%   1.4%   1.5%  
Other   5.1%   5.1%   3.7%   3.9%  
    100.0%   100.0%   100.0%   100.0%  

 

Note

* Based upon global payments received from consolidated Imaging Centers from that year's dates of service.

Excludes payments from hospital contracts, Breastlink, Imaging on Call, eRAD, Center Management Fees and other miscellaneous operating activities.

 

Footnotes

 

(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.

 

Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

 

 

 

 10 

 

 

(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.

 

Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.

 

 

 

 

 

 

 

 

 

 11